[1,2,4]TRIAZOLO[1,5-a]PYRIMIDINE DERIVATIVE

Publication number: WO03020723

Publication date: 2003-03-13

Inventor: ARAI HITOSHI (JP); MACHII DAISUKE (JP); HAGIHARA KOJI (JP); ICHIMURA MICHIO (JP); ENOKIZONO JUNICHI (JP); SHIOZAKI SHIZUO (JP); SHIMADA JUNICHI (JP); SUZUKI KOJI (JP)

Applicant: KYOWA HAKKO KOGYO KK (JP); ARAI HITOSHI (JP); MACHII DAISUKE (JP); HAGIHARA KOJI (JP); ICHIMURA MICHIO (JP); ENOKIZONO JUNICHI (JP); SHIOZAKI SHIZUO (JP); SHIMADA JUNICHI (JP); SUZUKI KOJI (JP)

Classification:

- international: ***A61K31/519; A61K31/5377; A61P25/16; A61P25/24; A61P25/28; A61P43/00; C07D487/04;*** **A61K31/519; A61K31/5375; A61P25/00; A61P43/00; C07D487/00;** (IPC1-7): C07D487/04; A61K31/519; A61K31/5377; A61P25/16; A61P25/24; A61P25/28; A61P43/00

- European: A61K31/519; A61K31/5377; C07D487/04

Application number: WO2002JP08666 20020828

Priority number(s): JP20010262095 20010830

Cited documents:

WO9943678

JP4099775

Abstract of **WO03020723**

A [1,2,4]triazolo[1,5-a]pyrimidine derivative represented by the formula I: I wherein Y represents hydrogen or unsubstituted lower alkyl Z represents oxygen or sulfur and X represents II or III or a pharmacologically acceptable salt of the derivative. They have an antagonistic activity against an adenosine A2A receptor and are useful for treatments for and/or prevention of various diseases attributable to the hyperenergia of an adenosine A2A receptor, e.g., parkinsonism.

A [1,2,4]triazolo[1,5-a]pyri midine derivative represented by the formula (I): (I) wherein Y represents hydrogen or (un)substituted lower alkyl; Z represents oxygen or sulfur; and X represents (II) or (III) or a pharmacologically acceptable salt of the derivative. They have an antagonistic activity against an adenosine A<sb>2A</sb> receptor and are useful for treatments for and/or prevention of various diseases attributable to the hyperenergia of an adenosine A<sb>2A</sb> receptor, e.g., parkinsonism.